Larry Goldenberg Appointed Chief Medical Officer-Urology
Omnitura Therapeutics Inc. (Omnitura) announced the appointment of Dr. Larry Goldenberg as Chief Medical Officer-Urology. In this role, Dr. Goldenberg plays a leadership role in shaping Omnitura's translational and clinical research plans for the management of prostate disorders such as prostate cancer.
Dr. Goldenberg currently serves as Professor and Chairman of the Department of Urologic Sciences at UBC, Director of Clinical Research at the Prostate Centre at Vancouver General Hospital, and a Fellow of the Canadian Academy of Health sciences. He is a co-founder of the Canadian Urologic-Oncology Group, and past-president of both the Canadian Urological Association and the Western section of the American Urological Association.
Through his vision and leadership, the Prostate Centre at Vancouver General Hospital has developed into one of the top prostate research, education and healthcare delivery programs in the world.
Dr. Larry Goldenberg was a pioneer in the use of intermittent hormone withdrawal for the management of prostate cancer, which is now used worldwide as a treatment option for this disease. His book, Prostate Cancer - All You Need to Know to Take an Active Part in Your Treatment, is considered one of the best reference sources for men with prostate disease in North America.
"We are very pleased by Dr. Goldenberg's decision to join our team," said Jim Dao, Chairman and CEO of Omnitura. "With his clinical perspective, expertise, and leadership we hope to further refine our translational and clinical development plans to maximize the benefit of our MFMT solutions to reduce mortality and suffering due to prostate cancer."